2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses using CAR T-cell therapy in solid tumors.
David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses using chimeric antigen receptor (CAR) T-cell therapy in solid tumors.
Currently, the 2 approved indications for CAR T-cell therapy are in hematologic malignancies. In solid malignancies, CAR T cells have not been effective to date, says Maloney.
Maloney says that it is likely that CAR T cells will have to be combined with other agents to have an effect in solid tumors.
Related Content: